幽門桿菌主要感染人類胃部並引起胃潰瘍、十二指腸潰瘍，以及與胃癌息息相關。目前在治療上以抗生素合併質子幫浦抑制劑的三重療法為主，但由於細菌抗藥性問題以及治療所延伸之副作用，使得抗生素療法仍有很大改善空間。乳酸菌已被用來改善腸胃道感染包括幽門桿菌感染，但不同菌種間的改善功能有所不同。因此本研究探討特定乳酸菌是否可以抑制幽門桿菌。由生合生物科技公司提供50株不同乳酸菌，以尋找具有高度抑菌能力之菌株。實驗發現乳酸菌11、乳酸菌33及乳酸菌37除了可以抑制一般幽門桿菌外，還可以抑制多重抗藥性之菌株，這些菌株在大氣及微需氧的培養環境下，對幽門桿菌皆有殺菌能力。濃縮無菌上清液可以抑制幽門桿菌的生長，其抑菌效果初步優於目前商品化優酪乳菌株。經高溫破壞培養液之蛋白質成分或改變培養液的pH值，證實這三株乳酸菌是透過所分泌的乳酸來殺死幽門桿菌。3株乳酸菌可吸附到胃細胞AGS與MKN45，顯示這三株有機會停留在胃部，但加入乳酸菌無法抑制幽門桿菌吸附至胃細胞AGS與MKN45之能力，顯示乳酸菌菌體本身可能不具有抑菌功能及降低IL-8表現量，也不會干擾人體清除致病菌的免疫反應。選用幽門桿菌菌株625進行小鼠實驗， 3株乳酸菌皆能在幽門桿菌感染後3週或6週內，於胃體部、胃竇部、或整體胃部中改善幽門桿菌所造成的急性或慢性發炎反IV應。綜合以上實驗，我們認為乳酸菌11、乳酸菌33、乳酸菌37三株菌具有減緩幽門桿菌感染的能力。 Helicobacter pylori can infect human’s stomach and cause gastric ulcer and duodenal ulcer. Moreover, it is intimately related to gastric cancer. Currently, antibiotics combined with proton pump inhibitor (PPI) are the major treatment. However, antibiotic treatment still requires to be improved due to the problem of drug resistance and the side effects. Lactobacilli have been used to improve the intestinal malfunction and diseases which included the H. pylori infection. Howerer, different genes and species may have different effects. This study aimed to explore lactic bacteria’s capability in inhibiting Helicobacter pylori. In order to find out high antimicrobial capability of lactic bacteria, Synbiotech Inc. Provided 50 lactic bacterial strains for this research. It was found that lactic acid bacteria 11, lactic bacteria 33 and lactic bacteria 37 can inhibit not only the common H. pylori but also multidrug resistance of H. pylori under the atmosphere and microaerophilic conditions. The concentrated supernatant of lactic bacteria inhibited the growth of H. pylori, and the effect of inhibition was better than currently commercial lactic bacteria. Destroyed protein components of culture supernatant through heat or change pH of culture media confirmed three lactic bacteria can secrete lactic acid to inhibit H. pylori. These lactic bacteria can adhere in AGS and MKN45 cell lines, suggesting they are able to stay in stomach. However, adding these lactic bacteria cannot prevent H. pylori from being adhered in AGS and MKN45 cell lines. Hence, there is a big possibility that lactic bacteria strains might not possess antibacterial ability and reduce the expression of IL-8. In addition, they do not appear to interfere with human immune response. In the animal model, we studied on the influenceVIbetween H. pylori strain 625 and lactic bacteria strains in mouse. After being infected by H. pylori, these lactic bacteria strains appear to decrease acute inflammation and chronic inflammation in body, antrum and whole stomach within three to six weeks. Based on this study, it is reasonable to assume lactic bacteria 11, lactic bacteria 33 and lactic bacteria 37 possess the ability to decrease the H. pylori infection.
